ABANZA Achieves FDA 510(k) Clearance for QuadLock™
ABANZA, a pioneer in soft-tissue repair solutions, has exciting news to share. The company has received 510(k) clearance from the U.S. Food and Drug Administration for its latest innovation, QuadLock™. This new system is a knotless, bidirectional tension-adjustable fixation option specifically crafted for ACL reconstruction.
About the QuadLock™ System
QuadLock™ stands out as an advanced fixation system designed to securely affix sutures and tapes, enabling surgeons to fine-tune graft tension. This feature is crucial for maintaining stability across various graft configurations commonly utilized in ACL surgeries, which include options like quadriceps tendon, quadrupled semitendinosus/gracilis, and bone–patellar tendon–bone.
Biomechanical Advantages
In rigorous biomechanical assessments, QuadLock™ has shown exceptional control over cyclic displacement, measuring less than 0.5 mm. This represents over a 500% improvement compared to traditional fixation techniques, which can see displacements of approximately 3–6 mm. Additionally, QuadLock™ boasts a pullout strength exceeding 1,000 N, ensuring high fixation strength while minimizing displacement. This stabilization is critical during early recovery, directly influencing the restoration of functional joint stability.
The Importance of ACL Reconstruction
ACL reconstruction continues to be a significant procedure in sports medicine, with around 300,000 surgeries conducted annually. With features like minimal cyclic displacement, knotless fixation, and adjustable tension, QuadLock™ broadens the options available to surgeons, enhancing graft management across different patient bone qualities.
Statements from Leadership
Juan Abascal, Chief Executive Officer of ABANZA, shares that "QuadLock™ reflects our commitment to practical innovation, affording surgeons the adjustability, control, and confidence needed during critical moments of fixation performance. As our patient demographics evolve, traditional methods face increasing scrutiny, underlining the importance of our advancements. This clearance reinforces our strategy to develop soft-tissue repair solutions with a focus on reproducible techniques and stable fixation, even under challenging conditions."
Future Developments and Product Line
QuadLock™ is part of a growing family of soft-tissue fixation technologies from ABANZA. The company is actively developing additional products like LoopCap™ and WasherCap™ In Line, which aim to expand the application of their offerings into areas such as biceps tendon repair, AC Joint reconstruction, and specialized Foot and Ankle surgeries, including Syndesmosis and Achilles repairs.
To stay updated on QuadLock™ and ABANZA's innovative product pipeline, prospective customers and medical professionals can visit their website.
About ABANZA
ABANZA is dedicated to advancing soft-tissue repair through groundbreaking fixation technologies. The company's mission is to support surgeons in delivering reliable outcomes for an evolving patient population. Their devices are carefully engineered to complement modern surgical techniques, ensuring consistent, dependable results in soft-tissue repair.
With an unwavering commitment to clinical excellence and constant innovation, ABANZA is creating a platform of solutions designed to elevate the standards of care while expanding the possibilities within the realm of soft-tissue repair.
Frequently Asked Questions
What is QuadLock™?
QuadLock™ is an advanced fixation system designed for ACL reconstruction, featuring knotless, adjustable tension capabilities.
What are the key benefits of using QuadLock™?
Key benefits include minimal cyclic displacement, high pullout strength, and enhanced graft tension adjustment, improving patient outcomes.
How does QuadLock™ compare to traditional fixation methods?
QuadLock™ offers superior control of cyclic displacement, with less than 0.5 mm compared to 3–6 mm from conventional options.
Who is the CEO of ABANZA?
Juan Abascal is the Chief Executive Officer of ABANZA, emphasizing innovation and patient care in the company's strategies.
What other products is ABANZA developing?
ABANZA is also developing LoopCap™ and WasherCap™ In Line to broaden their fixation technology portfolio for various surgical applications.
